Tirzepatide Shows Promise in Diabetes Prevention and Weight Loss
TL;DR Summary
A study published in the New England Medical Journal reveals that tirzepatide, the active ingredient in Eli Lilly's Mounjaro, significantly reduces the risk of developing diabetes by 94% in high-risk individuals. Conducted over three years with over 2500 pre-diabetic participants, the trial showed that only 1.3% of those taking tirzepatide developed diabetes compared to 13.3% in the placebo group. The drug, which mimics the body's feeling of fullness, also led to substantial weight loss and maintained blood sugar control, suggesting long-term protective benefits against diabetes.
- Mounjaro Appears to Be Extremely Effective at Preventing Diabetes Futurism
- Ozempic Could Prevent Diabetes. Should It Be Used for That? The New York Times
- SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity TCTMD
- Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free Reuters
- Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks Investors | Eli Lilly and Company
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
80%
415 → 85 words
Want the full story? Read the original article
Read on Futurism